Literature DB >> 21911320

Ischemia-modified albumin and total antioxidant status in patients with slow coronary flow: a pilot observational study.

Fatih Koç1, Sami Erdem, Fatih Altunkaş, Kerem Ozbek, Enes Elvin Gül, Sevil Kurban, Erkan Taşyürek, Ekrem Erbay, Erkan Söğüt.   

Abstract

OBJECTIVE: Slow coronary flow (SCF) is defined as late opacification in the epicardial coronary arteries without significant stenosis. The underlying mechanism of SCF is similar to coronary atherosclerosis. Free radical damage may be responsible for the pathology. In this study, we aimed to investigate ischemia-modified albumin (IMA) levels and differences with regard to total antioxidant status (TAS) between patients with normal coronary arteries and patients with SCF without significant stenosis.
METHODS: Thirty patients who were diagnosed with SCF using coronary angiography were included in this cross-sectional observational study (13 male; mean age, 56±10 years). The control group consisted of 30 patients who had normal coronary arteries as shown by coronary angiography (13 male; mean age, 53±11 years). In this study, we assessed serum IMA levels, albumin-adjusted IMA and TAS. The Student t-test was used to compare serum IMA levels and TAS between the two groups. Pearson's correlation test was used to explore the relationship between TAS and serum IMA levels.
RESULTS: Serum IMA levels and albumin-adjusted IMA were similar in both groups (p=0.432, p=0.349). The mean value of TAS was significantly lower in the SCF group compared to control group (p=0.011). The TAS was negatively correlated with the levels of IMA and albumin-adjusted IMA in the SCF group (r=-0.457, p=0.011; r=-0.509, p=0.004).
CONCLUSION: This study shows that serum IMA levels and albumin-adjusted IMA were similar between the groups, however the mean value of TAS was significantly lower in the SCF group compared to control group and negatively correlated with IMA. These results are important in terms of understanding the pathophysiological basis of SCF.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21911320     DOI: 10.5152/akd.2011.159

Source DB:  PubMed          Journal:  Anadolu Kardiyol Derg        ISSN: 1302-8723


  4 in total

1.  The association of serum albumin with coronary slow flow.

Authors:  Mustafa Cetin; Cemil Zencir; Hakan Tasolar; Erkan Baysal; Mehmet Balli; Erdal Akturk
Journal:  Wien Klin Wochenschr       Date:  2014-07-01       Impact factor: 1.704

2.  Association of eosinophil-to-lymphocyte ratio with coronary slow-flow phenomenon in patients undergoing coronary angiography.

Authors:  Aydın Rodi Tosu; Muhsin Kalyoncuoğlu; Halil İbrahim Biter; Sinem Çakal; Beytullah Çakal; Murat Selçuk; Tufan Çinar
Journal:  Arch Med Sci Atheroscler Dis       Date:  2022-07-07

3.  Ischemia-modified albumin must be evaluated as an oxidative stress marker together with albumin and bilirubin in individuals with acute appendicitis.

Authors:  Varikasuvu Seshadri Reddy; Balananda Perugu; Mohinder Kumar Garg
Journal:  Clinics (Sao Paulo)       Date:  2015-07-01       Impact factor: 2.365

4.  Ischemia-modified albumin levels in patients with acute decompensated heart failure treated with dobutamine or levosimendan: IMA-HF study.

Authors:  Yüksel Çavuşoğlu; Şule Korkmaz; Selda Demirtaş; Erkan Gencer; Hatice Şaşmaz; Fezan Mutlu; Hakan Güneş; Uğur Kadir Mert; Sedat Özdemir; Süleyman Kalaycı; Mehmet Birhan Yılmaz
Journal:  Anatol J Cardiol       Date:  2015-08       Impact factor: 1.596

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.